Overview

Study to Evaluate CCS1477 in Advanced Tumours

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer (mCRPC) or advanced solid tumours.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

CellCentric Ltd.

Treatments:

Abiraterone Acetate